Peptide nasal spray vs injection is a trade-off between convenience and dependable absorption. Injections deliver most of a peptide dose into the body. Approved nasal peptide drugs absorb only a few percent: about 3% to 5% for calcitonin compared with injection, 3.3% to 4.1% for desmopressin and 2.8% for nafarelin.[2][3][4] Some nasal peptides may reach the brain directly. Large trials of intranasal insulin and oxytocin found no benefit for their target conditions.[1][6][7]
This guide is part of our peptide basics hub. For injection routes, see subcutaneous vs intramuscular injection.
Nasal spray vs injection at a glance
| Nasal spray or powder | Injection (usually subcutaneous) | |
|---|---|---|
| Absorption | Low and variable; a few percent for approved nasal peptides[2][3][4] | High and predictable for approved products[9] |
| Speed | Can be fast; nasal glucagon peaks around 15 minutes[5] | Varies by drug and site |
| Brain access | Possible nose-to-brain route, poorly understood[1] | Limited by the blood-brain barrier |
| Needles | None | Required |
| Common side effects | Nasal irritation, congestion, nosebleeds[5] | Injection-site reactions[9] |
| Approved US examples | Desmopressin, calcitonin, nafarelin, glucagon[2][3][4][5] | Semaglutide, tesamorelin, many others[9] |
How nasal delivery works
The inside of the nose has a thin lining with a rich blood supply, so small molecules can enter the bloodstream quickly. Peptides are harder: they are larger and break down easily. Drug developers have tried modifying peptides and adding delivery aids to improve uptake.[1]
The nose also offers a possible shortcut to the brain, along the olfactory and trigeminal nerves. A 2025 review noted that nose-to-brain delivery is already used in the clinic but that the underlying mechanisms are still poorly understood.[1]
Approved nasal peptide drugs and their bioavailability
FDA labels give hard numbers for how much of a nasal dose reaches the blood:
| Drug | Use | Nasal bioavailability |
|---|---|---|
| Calcitonin-salmon nasal spray | Postmenopausal osteoporosis, when other treatments aren’t suitable | 3% to 5% relative to intramuscular injection[2] |
| Desmopressin (Stimate) | Bleeding in hemophilia A and von Willebrand disease | 3.3% to 4.1% absolute[3] |
| Nafarelin (Synarel) | Endometriosis, early puberty | 2.8% on average (range 1.2% to 5.6%)[4] |
| Glucagon (Baqsimi) | Severe low blood sugar | 3 mg nasal dose; peak levels at about 15 minutes[5] |
These products work because their doses are set for nasal absorption and tested in trials. Even so, the calcitonin label notes that fracture reduction has not been shown.[2]
Why your nose matters to the dose
Nasal absorption depends on the state of the nasal lining. Labels for desmopressin and calcitonin warn that scarring, swelling or other nasal disease can cause erratic, unreliable absorption; Stimate’s label says to stop the spray until nasal problems resolve.[2][3] A cold or allergies can therefore change how much drug you get, which is rarely a concern with injections.
Devices matter too. Calcitonin spray is given as one 200 IU spray a day, alternating nostrils, after the pump is primed before first use.[2] Nasal glucagon is a single-use powder device, and the dose does not need to be inhaled, which is why someone else can give it during a severe low-sugar episode.[5] The intranasal insulin trial below showed how much the device matters: its first device was unreliable and had to be replaced partway through.[6]
What intranasal peptide research shows
Two large, well-run trials tested the brain-delivery idea directly:
- Intranasal insulin for memory (2020): in a 12-month, double-blind trial at 27 US sites, 289 adults with mild cognitive impairment or mild Alzheimer disease dementia received 40 IU of nasal insulin or placebo daily. In the main analysis of 240 participants, there was no cognitive or functional benefit, and no clinically important adverse events were linked to treatment.[6]
- Intranasal oxytocin for autism (2021): in a 24-week trial of 290 children and adolescents, a target dose of 48 IU daily did not improve social withdrawal scores compared with placebo, and secondary outcomes generally didn’t differ. Side effects were similar in both groups.[7]
Read more in our oxytocin profile.
Russian nasal peptides
Semax and Selank are seven-amino-acid peptides used as nasal sprays in Russia; their human studies are small and mostly Russian. Neither is FDA-approved. Both were nominated for US compounding, and the nominations were withdrawn. FDA noted possible immune-reaction risks from aggregation and impurities and limited human safety information.[8] FDA also placed GHRP-2 for injectable and nasal use in Category 2 for 503B compounding, citing immune-reaction risk.[8]
Side effects and safety
- Nasal irritation: Baqsimi’s most common side effects include runny nose, nasal discomfort, congestion and nosebleeds, along with nausea, vomiting and headache.[5]
- Nasal damage: calcitonin nasal spray can cause nasal ulceration, including severe ulcers, and its label recommends periodic nasal examinations.[2]
- The drug still acts in the body: desmopressin nasal spray carries warnings about low blood sodium (hyponatremia) and water intoxication.[3] Calcitonin labeling advises re-evaluating long-term use because of a possible link with cancer.[2]
- Homemade sprays: turning an injectable peptide into a nasal spray is untested, absorption would be unpredictable, and a non-sterile bottle adds contamination risk.
Legal status and cost
A nasal spray is legal when it is an FDA-approved product or properly compounded under federal rules. Research peptides sold as nasal sprays are not approved for human use.[8] Costs vary by drug. Because only a small share of a nasal dose is absorbed, nasal products may need far more peptide per dose than injections. For the legal differences, see compounded vs research-grade peptides.
Which might suit you?
Questions to ask your clinician:
- Is there an approved nasal version of the drug you need? If so, it has tested dosing.[2][3]
- Do you need fast action without a needle? Nasal glucagon is designed for emergencies.[5]
- Is the “brain benefit” claim backed by trials? For insulin and oxytocin, large trials say no.[6][7]
Product form matters too; see lyophilized vs premixed peptides.
The verdict
Injections remain the reliable way to deliver most peptides, which is why drugs like semaglutide are injected.[9] Nasal delivery works for a handful of approved peptides designed and dosed for it, usually with absorption of 5% or less.[2][3][4] Nose-to-brain delivery is an active research area, but the best trials so far have not delivered the hoped-for benefits.[6][7]
